Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes.
Aged
Aged, 80 and over
Choroidal Neovascularization
/ classification
Female
Follow-Up Studies
Humans
Intravitreal Injections
Macular Degeneration
/ drug therapy
Male
Ranibizumab
/ administration & dosage
Receptors, Vascular Endothelial Growth Factor
/ administration & dosage
Recombinant Fusion Proteins
/ administration & dosage
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
01
2021
revised:
19
04
2021
accepted:
19
05
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
23
9
2021
Statut:
epublish
Résumé
To evaluate the effects of anti-VEGF treatment of neovascular age-related macular degeneration (nAMD) in a real-life clinical setting. Study design is a retrospective case series. Naïve nAMD patients treated with intravitreal injection of aflibercept or ranibizumab were analyzed over a 24-month follow-up. Each patient received the loading dose, followed by a PRN regimen. Patients were further subdivided into subgroups according to macular neovascularization type, best corrected visual acuity (BCVA) at baseline (BCVA > 0.3 LogMAR and BCVA ≤ 0.3 LogMAR), and different anti-VEGF drugs. Primary outcome was the changes in BCVA and central macular thickness (CMT) over 24 months. Secondary outcomes included the influence of the selected drug and of the baseline BCVA on the final outcomes. 439 patients (224 males; 51%) with naïve AMD-related macular neovascularization were included in the analyses. Mean age was 78 ± 8 years old. Compared to baseline evaluations, not significant BCVA changes were found at 1-year and 2-year examinations. CMT was significantly reduced at both 1-year and 2-year follow-ups ( Anti-VEGF approach is generally effective in stopping nAMD progression in our real-life analysis. No difference was found comparing patients treated with ranibizumab and aflibercept, nor in patients with drug switching.
Identifiants
pubmed: 34124243
doi: 10.1155/2021/5516981
pmc: PMC8169263
doi:
Substances chimiques
Recombinant Fusion Proteins
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Ranibizumab
ZL1R02VT79
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5516981Informations de copyright
Copyright © 2021 Alessandro Arrigo et al.
Déclaration de conflit d'intérêts
None of the authors has a conflict of interest to declare.
Références
Ophthalmology. 2014 May;121(5):1092-101
pubmed: 24461586
Ophthalmology. 2009 Jan;116(1):57-65.e5
pubmed: 19118696
Arch Ophthalmol. 2004 Apr;122(4):564-72
pubmed: 15078675
Clin Ophthalmol. 2017 Apr 18;11:715-721
pubmed: 28458510
PLoS One. 2015 Aug 04;10(8):e0135050
pubmed: 26241852
Br J Ophthalmol. 2003 Mar;87(3):307-11
pubmed: 12598444
J Ocul Pharmacol Ther. 2017 Sep;33(7):567-572
pubmed: 28557667
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):647-55
pubmed: 24424409
Eur J Ophthalmol. 2020 Nov;30(6):1461-1466
pubmed: 31617403
Br J Ophthalmol. 2014 Jul;98(7):951-5
pubmed: 24518078
Ophthalmology. 2016 Feb;123(2):337-343
pubmed: 26578446
Retina. 2016 Aug;36(8):1418-31
pubmed: 27388744
Ophthalmology. 2007 Oct;114(10):1868-75
pubmed: 17628683
BMJ Open Ophthalmol. 2019 Apr 9;4(1):e000109
pubmed: 31179386
Ophthalmology. 2015 Jun;122(6):1212-9
pubmed: 25846847
Acta Ophthalmol. 2019 Feb;97(1):e1-e7
pubmed: 30030923
Retina. 2016 Dec;36 Suppl 1:S40-S49
pubmed: 28005662
Control Clin Trials. 1999 Dec;20(6):573-600
pubmed: 10588299
N Engl J Med. 2008 Jun 12;358(24):2606-17
pubmed: 18550876
Prog Retin Eye Res. 2001 May;20(3):385-414
pubmed: 11286898